Main description:

* First book dedicated to this disease, previously thought to be incurable, but with the advent of new drugs, now amenable to management and a much improved prognosis for patients * From the PAH Association, the leading experts in field * Incorporates the latest AACP management guidelines * Includes evidence-based treatment algorithms based on the recently updated ACCP Guidelines for Medical Treatment * Aimed at specialists in pulmonology and cardiovascular disease, this volume provides the clinician with the most up to date information on the effective management of PAH

Contents:

Preface Contributors. 1 Introduction ( Robyn J. Barst ). 2 Diagnosis and assessment of pulmonary arterial hypertension ( Michael D. McGoon, Adam Torbicki and Ronald J. Oudiz ). 2.1 Hemodynamics of pulmonary hypertension. 2.2 Venice classification. 2.3 Overview of the diagnostic process (algorithm). 2.4 Screening (identifying a pre-existing risk). 2.5 Detection (discovering pulmonary hypertension). 2.6 Definition (diagnosing the clinical context). 2.7 Prediction (estimating prognosis). 2.8 Principles of follow-up (evaluating and responding to outcome). 2.9 Specific tests in the evaluation of pulmonary hypertension. 3 Conventional therapy in pulmonary arterial hypertension ( Richard N. Channick ). 3.1 Calcium channel antagonists. 3.2 Diuretics. 3.3 Warfarin. 3.4 Supplemental oxygen. 3.5 Inotropic therapy. 3.6 General measures. 3.7 Conclusions. 4 Prostanoid treatment for pulmonary arterial hypertension ( Olivier Sitbon and Gerald Simonneau ). 4.1 Epoprostenol. 4.2 Treprostinil. 4.3 Iloprost. 4.4 Beraprost. 4.5 Treatment selection. 4.6 Conclusions. 5 Endothelin receptor antagonists in pulmonary arterial hypertension ( David B. Badesch and Marc Humbert ). 5.1 Bosentan. 5.2 Sitaxsentan. 5.3 Ambrisentan. 5.4 Safety and tolerability with endothelin receptor antagonists. 5.5 Conclusions. 6 Phosphodiesterase-5 inhibitors in pulmonary arterial hypertension ( Hossein A. Ghofrani, Werner Seeger and Friedrich Grimminger ). 6.1 The origins of phosphodiesterase-5 inhibitor development. 6.2 Pulmonary hypertension as a new indication for phosphodiesterase-5 inhibitor treatment. 6.3 Role of phosphodiesterase-5 in the pulmonary vasculature. 6.4 Clinical experience with sildenafil for the treatment of chronic pulmonary hypertension. 6.5 Pivotal trial and approval of sildenafil for the treatment of pulmonary arterial hypertension (SUPER-1 study). 6.6 Other phosphodiesterase-5 inhibitors. 6.7 Combination therapy. 6.8 Potential new indications for phosphodiesterase-5 inhibitors outside pulmonary arterial hypertension. 6.9 Conclusions. 7 Combination therapy for pulmonary arterial hypertension ( Anne Keogh and Marius Hoeper ). 7.1 Background. 7.2 Combination therapy to date. 7.3 Conclusions. 8 Interventional and surgical modalities of treatment for pulmonary arterial hypertension ( Julio Sandoval and Ramona Doyle ). 8.1 Introduction. 8.2 Atrial septostomy. 8.3 Pulmonary endarterectomy in chronic thromboembolic pulmonary hypertension. 8.4 Lung transplantation for pulmonary hypertension. 8.5 Conclusions. 9 End points and clinical trial design in pulmonary arterial hypertension: Clinical and regulatory perspectives ( Andrew J. Peacock ). 9.1 Introduction. 9.2 Trial design. 9.3 End points in trials of therapy for pulmonary arterial hypertension. 9.4 Conclusions. 10 Comparative analysis of clinical trials and evidence-based treatment algorithm for pulmonary arterial hypertension ( Nazzareno Galie, Alessandra Manes, Naushad Hirani and Robert Naeije ). 10.1 Introduction. 10.2 Randomized controlled studies. 10.3 Long-term continuation studies. 10.4 Combination studies. 10.5 Evidence-based treatment algorithm. 10.6 Conclusions. 11 Diagnosis and assessment of non-pulmonary arterial hypertension masquerading as idiopathic pulmonary arterial hypertension: Diastolic heart failure - evaluation and interactions ( Mardi Gomberg-Maitland and Stuart Rich ). 11.1 Definition of heart failure. 11.2 Epidemiology. 11.3 Physiology. 11.4 Evaluation of diastolic heart failure: Invasive and noninvasive techniques. 11.5 Diagnosis and treatment of diastolic dysfunction. 11.6 Pulmonary hypertension and diastolic dysfunction. 11.7 Conclusions. 12 Treatment of pulmonary arterial hypertension: A look to the future ( Lewis J. Rubin ). 12.1 Therapy of pulmonary arterial hypertension. 12.2 Measuring outcomes and monitoring the course of therapy. 12.3 Conclusions. Index.